Mineralys Therapeutics Inc. (MLYS) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Mineralys Therapeutics In... (MLYS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

9.10

-0.26 (-2.78%)

At close: Jan 14, 2025, 3:59 PM

8.90

-2.20%

Pre-market Jan 15, 2025, 05:47 AM EST

undefined% (undefined)

Bid	3.65
Market Cap	452.89M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.31
PE Ratio (ttm)	-2.75
Forward PE	n/a
Analyst	Buy

Ask	14.59
Volume	254,257
Avg. Volume (20D)	205,781
Open	9.36
Previous Close	9.36
Day's Range	8.90 - 9.39
52-Week Range	7.95 - 16.91
Beta	undefined

About MLYS

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 10, 2023

Employees 28

Stock Exchange NASDAQ

Ticker Symbol MLYS

Website https://mineralystx.com

Analyst Forecast

According to 2 analyst ratings, the average rating for MLYS stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 229.67% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

5 months ago · Source

-22.82%

Mineralys Therapeutics shares are trading lower af... Unlock content with Pro Subscription

11 months ago · Source

+12.51%

Mineralys Therapeutics shares are trading higher after the company announced $120 million in private placement financing.

News

2 months ago · seekingalpha.com

Mineralys Therapeutics, Inc. (MLYS) Q3 2024 Earnings Call Transcript

Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam...